Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Ibrexafungerp Activity at Acidic pH Against Vaginal Candida
2026-05-23
This study demonstrates that ibrexafungerp retains potent antifungal activity against fluconazole-susceptible and -resistant vaginal Candida isolates, even under acidic conditions representative of the vaginal environment. The findings highlight ibrexafungerp’s translational relevance for treating vulvovaginal candidiasis, particularly in cases where azole resistance and low pH limit standard therapy efficacy.
-
CF10 and EdU Synergy Induces Telomere Attrition in CRC Cells
2026-05-22
This study reveals that the fluoropyrimidine polymer CF10, when combined with 5-ethynyl-2′-deoxyuridine (EdU), promotes telomere attrition and mitotic catastrophe in colorectal cancer cells. The findings suggest a novel mechanism for enhancing cancer cell death by targeting telomere maintenance, offering new directions for telomerase-focused therapeutic strategies.
-
Busulfan as a DNA Alkylating Agent: Experimental Workflows &
2026-05-22
Busulfan’s unique DNA alkylating action empowers robust modeling of cellular senescence and germ cell depletion, enabling advanced in vitro and in vivo workflows for genetic tracing and reproductive biology. This guide details optimized protocols, troubleshooting strategies, and the scientific impact of Busulfan in lineage-tracing studies, with actionable insights for maximizing reproducibility and interpretability.
-
Rifampin in Research: Applied Workflows & Troubleshooting Ti
2026-05-21
Rifampin, the benchmark rifamycin antibiotic, empowers researchers with precise transcription inhibition for bacterial resistance studies, synthetic biology, and antibiotic drug research. Explore advanced workflows, protocol enhancements, and troubleshooting strategies that maximize reliability and reproducibility in experimental settings.
-
Biomimetic Chromatography for Modeling Pulmonary Drug Permea
2026-05-21
The reference study introduces robust biomimetic chromatographic techniques—IAM-LC and OT-CEC—coupled with mass spectrometry to model lung permeability for pharmaceuticals. These methods offer improved predictive power for pulmonary drug absorption and facilitate high-throughput screening, with specific relevance for anti-inflammatory corticosteroids in respiratory disease research.
-
Thrombin in Fibrin Matrices: Redefining Vascular Models
2026-05-20
This thought-leadership article explores how the mechanistic versatility of thrombin as a trypsin-like serine protease at the heart of the coagulation cascade is driving new frontiers in translational vascular biology. By integrating recent evidence on endothelial invasion in fibrin matrices and leveraging ultra-pure reagents such as APExBIO's Coagulation Factor II (Thrombin) B Chain Fragment, we offer actionable guidance for researchers building next-generation angiogenesis and coagulation assays that bridge basic science and clinical relevance.
-
Obacunone Drives Ferroptosis in Ovarian Cancer via Akt/p53 A
2026-05-20
This study uncovers how Obacunone, a natural compound, induces ferroptosis in ovarian cancer cells by modulating the Akt/p53 pathway. The findings highlight a mechanistic link between Akt inhibition, p53 activation, and iron-dependent cell death, offering a new direction for ovarian cancer therapy research.
-
CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1
2026-05-19
The reference study reveals that Cdc2-like kinase 2 (CLK2) is upregulated in ovarian cancer and confers platinum resistance by phosphorylating BRCA1, enhancing DNA repair. These insights provide a mechanistic basis for targeting CLK2 to overcome chemotherapy resistance, with significant implications for improving ovarian cancer treatment outcomes.
-
Ibrexafungerp Retains Potent Activity Against Vaginal Candid
2026-05-19
This study demonstrates that ibrexafungerp (MK 3118) maintains potent in vitro antifungal activity against both fluconazole-susceptible and -resistant vaginal Candida isolates at acidic pH, closely mirroring the vaginal environment in vulvovaginal candidiasis (VVC). The findings highlight ibrexafungerp’s unique suitability for treating VVC, especially in cases where azole resistance limits therapeutic options.
-
MALAT1/miR-125b/STAT3 Axis Regulates PCT Expression in Sepsi
2026-05-18
This study uncovers a mechanistic link between the long noncoding RNA MALAT1, miR-125b, and STAT3 signaling in regulating procalcitonin (PCT) expression in sepsis. By elucidating the MALAT1-mediated ceRNA network's influence on STAT3 and PCT, the work refines our understanding of sepsis biomarkers and highlights potential molecular targets for improved diagnostic and therapeutic approaches.
-
Gepotidacin (GSK2140944): Transforming Antibacterial Researc
2026-05-18
Gepotidacin (GSK2140944) offers a first-in-class solution for combating antibiotic resistance, with a unique mode of action targeting bacterial type II topoisomerases. This article guides experimentalists through optimized workflows, troubleshooting, and advanced applications to maximize reproducibility and impact in antibacterial research.
-
Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Proto
2026-05-17
The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents proteolytic degradation during protein extraction and sample preparation, especially in workflows where EDTA could interfere with divalent cation-dependent assays. It is not suitable for protocols where metalloprotease inhibition via chelation is required, as it lacks EDTA.
-
Evaluating Protease Inhibitor Libraries for SARS-CoV-2 Drug
2026-05-16
This review analyzes the design and utility of commercial protease inhibitor libraries for virtual screening and drug design, specifically in the context of SARS-CoV-2. The paper highlights gaps in design transparency, documentation, and compound diversity, impacting the reliability of these resources for high-throughput drug discovery.
-
Rotavirus-Induced Downregulation of Nrf2: Mechanisms and Imp
2026-05-15
This study delineates how progressive rotavirus infection actively suppresses the redox-sensitive transcription factor Nrf2 and its downstream cytoprotective genes, highlighting a viral strategy to undermine host antioxidant defenses. The findings provide a mechanistic foundation for exploring Nrf2-modulating interventions in viral pathogenesis and cellular stress research.
-
Fluorescein TSA Fluorescence System Kit: Amplifying Sensitiv
2026-05-15
The Fluorescein TSA Fluorescence System Kit delivers unrivaled sensitivity for detecting low-abundance targets in fixed cells and tissues via robust tyramide signal amplification. This article unpacks experimental workflows, real-world troubleshooting, and key innovations—translating reference study insights into actionable protocol enhancements for modern immunohistochemistry, immunocytochemistry, and in situ hybridization.
8290 records 12/553 page Previous Next First page 上5页 1112131415 下5页 Last page